Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
sanofi pasteur exercises option on Intercell’s bacterial vaccine antigens - up to EUR 23 m license and milestone payments

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
01.07.2005
Vienna - July 1, 2005 - Intercell AG (VSE - "ICLL") today announced
that its partner sanofi pasteur S.A. (previously aventis pasteur
S.A.), the vaccines business of the sanofi-aventis group, exercised
its option on exclusive worldwide commercial rights on certain
bacterial vaccine antigens, which have been identified by Intercell’s
Antigen Identification Program under a Collaboration and License
Option Agreement the parties concluded in December 2003.
The option exercise will trigger license fees and recognition of
previously unearned research funding and success fees resulting in an
aggregate value of about EUR 3 million. Over the entire term of the
agreement Intercell will be entitled to further milestone based
license payments totaling to about EUR 20  million, as well as
royalties on future net sales.
"Our partner sanofi pasteur is a leader and innovator in the field of
vaccines and we are delighted that our Antigen Identification Program
has again successfully delivered attractive vaccine antigens for
another important bacterial indication with a high unaddressed
medical need," states Intercell’s Chief Operating Officer, Gerd
Zettlmeissl.
"Intercell’s Antigen Identification Program is a very promising new
technology for the field of vaccine development", commented Michel
DeWilde, Executive Vice-president, Research and Development at sanofi
pasteur.  "We are impressed with the excellent progress Intercell has
made in this important project."
About Intercell AG Intercell AG is a fast growing biotechnology
company focusing on the design and development of novel vaccines for
prevention and treatment of diseases with substantial unaddressed
medical need. The Company’s unique position is based on the
combination of antigens and immunizers (adjuvants) derived from its
proprietary technology platforms and its in-house GMP manufacturing
facilities. Intercell’s technology has been endorsed by collaborative
agreements with a number of global pharmaceutical companies,
including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the
Statens Serum Institut. The Company has a broad development pipeline
with a vaccine for Japanese Encephalitis about to enter Phase III, a
vaccine for Hepatitis C undergoing Phase II trials, and five products
focused on infectious diseases in the pre-clinical phase. Intercell
is listed on the Vienna stock exchange under the symbol "ICLL". For
more information please visit: www.intercell.com
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
end of announcement                               euro adhoc 01.07.2005 08:02:13

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Börsen: Wiener Börse AG

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG